

ZONAGEN INC  
Form 8-K  
July 27, 2005

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
Current Report Filed Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934  
Date of Report  
(Date of earliest event reported): July 27, 2005  
Zonagen, Inc.  
(Exact name of registrant as specified in its charter)**

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**001-15281**  
(Commission File Number)

**76-0233274**  
(I.R.S. Employer Identification No.)

**2408 Timberloch Place, Suite B-1  
The Woodlands, Texas 77380**  
(Address of principal executive offices and zip code)  
**(281) 719-3400**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Information**

Zonagen, Inc. (the Company ) announced in a press release on July 27, 2005 that the Company s contract data management organization has completed the final data assessment associated with the Phase I/b clinical trial the Company completed earlier this year which was presented on a preliminary basis by Dr. Ronald Wiehle, the Company s Director of R&D, on February 24, 2005 on the effects of Proellex on fibroid size at the Advances in Uterine Leiomyoma Research: NIH 2<sup>nd</sup> International Congress .

A copy of the Company s press release is attached hereto as Exhibit 99.1. The press release is incorporated by reference herein and the foregoing description of the press release is qualified in its entirety by reference to the attached exhibit.

**Item 9.01. Financial Statements and Exhibits**

c. Exhibits

Exhibit Number	Description
99.1	Press Release dated July 27, 2005.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Zonagen, Inc.**

Date: July 27, 2005.

By: /s/ Louis Ploth, Jr.  
Louis Ploth, Jr.  
Vice President, Business Development  
and  
Chief Financial Officer

---

**EXHIBIT INDEX**

Exhibit Number	Description
99.1	Press Release dated July 27, 2005.